Sheaff Brock Investment Advisors LLC decreased its stake in Eli Lilly And Co (NYSE:LLY) by 35.8% in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 26,039 shares of the company’s stock after selling 14,518 shares during the period. Sheaff Brock Investment Advisors LLC’s holdings in Eli Lilly And Co were worth $2,794,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds also recently modified their holdings of the company. BlackRock Inc. increased its stake in shares of Eli Lilly And Co by 1.3% in the second quarter. BlackRock Inc. now owns 66,644,897 shares of the company’s stock valued at $5,686,808,000 after buying an additional 864,451 shares during the period. Janus Henderson Group PLC increased its stake in shares of Eli Lilly And Co by 7.5% in the second quarter. Janus Henderson Group PLC now owns 10,008,768 shares of the company’s stock valued at $854,049,000 after buying an additional 700,582 shares during the period. Bank of New York Mellon Corp increased its stake in shares of Eli Lilly And Co by 0.3% in the third quarter. Bank of New York Mellon Corp now owns 9,501,142 shares of the company’s stock valued at $1,019,568,000 after buying an additional 27,009 shares during the period. Morgan Stanley increased its stake in shares of Eli Lilly And Co by 37.8% in the second quarter. Morgan Stanley now owns 4,473,537 shares of the company’s stock valued at $381,727,000 after buying an additional 1,227,888 shares during the period. Finally, Bank of Montreal Can increased its stake in shares of Eli Lilly And Co by 4.6% in the third quarter. Bank of Montreal Can now owns 4,330,654 shares of the company’s stock valued at $464,722,000 after buying an additional 191,374 shares during the period. 76.91% of the stock is owned by institutional investors.

NYSE LLY opened at $114.83 on Monday. Eli Lilly And Co has a one year low of $73.69 and a one year high of $116.61. The company has a market cap of $120.58 billion, a P/E ratio of 26.83, a price-to-earnings-growth ratio of 1.78 and a beta of 0.29. The company has a quick ratio of 1.53, a current ratio of 1.91 and a debt-to-equity ratio of 0.83.

Eli Lilly And Co (NYSE:LLY) last released its earnings results on Tuesday, November 6th. The company reported $1.39 EPS for the quarter, topping the consensus estimate of $1.35 by $0.04. Eli Lilly And Co had a return on equity of 42.84% and a net margin of 1.85%. The business had revenue of $6.06 billion during the quarter, compared to analysts’ expectations of $6.04 billion. During the same quarter last year, the firm posted $1.05 earnings per share. The firm’s revenue was up 7.1% on a year-over-year basis. As a group, research analysts predict that Eli Lilly And Co will post 5.58 EPS for the current fiscal year.

The company also recently disclosed a quarterly dividend, which will be paid on Monday, December 10th. Shareholders of record on Thursday, November 15th will be paid a $0.5625 dividend. The ex-dividend date is Wednesday, November 14th. This represents a $2.25 dividend on an annualized basis and a yield of 1.96%. Eli Lilly And Co’s dividend payout ratio (DPR) is presently 52.57%.

In other Eli Lilly And Co news, insider Donald A. Zakrowski sold 600 shares of the firm’s stock in a transaction that occurred on Tuesday, September 4th. The stock was sold at an average price of $105.57, for a total value of $63,342.00. Following the completion of the sale, the insider now owns 3,530 shares of the company’s stock, valued at $372,662.10. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, major shareholder Lilly Endowment Inc sold 14,632 shares of the firm’s stock in a transaction that occurred on Monday, October 8th. The shares were sold at an average price of $115.91, for a total value of $1,695,995.12. Following the completion of the sale, the insider now directly owns 119,191,172 shares of the company’s stock, valued at approximately $13,815,448,746.52. The disclosure for this sale can be found here. Insiders sold 1,732,900 shares of company stock valued at $119,875,245 in the last three months. Insiders own 0.11% of the company’s stock.

Several equities research analysts recently commented on LLY shares. TheStreet raised Eli Lilly And Co from a “c+” rating to a “b+” rating in a research note on Tuesday, November 6th. Wolfe Research started coverage on Eli Lilly And Co in a research note on Tuesday, October 23rd. They set a “market perform” rating and a $119.00 target price for the company. Credit Suisse Group raised their target price on Eli Lilly And Co from $84.00 to $86.00 and gave the stock an “underperform” rating in a research note on Wednesday, July 25th. Goldman Sachs Group set a $100.00 target price on Eli Lilly And Co and gave the stock a “neutral” rating in a research note on Wednesday, July 25th. Finally, BMO Capital Markets raised Eli Lilly And Co from a “market perform” rating to an “outperform” rating and raised their target price for the stock from $107.00 to $130.00 in a research note on Thursday, October 4th. Eight investment analysts have rated the stock with a hold rating and twelve have issued a buy rating to the company. The stock currently has an average rating of “Buy” and a consensus price target of $111.19.

TRADEMARK VIOLATION WARNING: This piece of content was posted by Daily Political and is the property of of Daily Political. If you are accessing this piece of content on another publication, it was stolen and republished in violation of US & international copyright & trademark legislation. The correct version of this piece of content can be viewed at https://www.dailypolitical.com/2018/11/19/sheaff-brock-investment-advisors-llc-sells-14518-shares-of-eli-lilly-and-co-lly.html.

Eli Lilly And Co Profile

Eli Lilly and Company discovers, develops, manufactures, and markets pharmaceutical products worldwide. The company operates through two segments, Human Pharmaceutical Products and Animal Health Products. It offers endocrinology products for the treatment of diabetes; osteoporosis in postmenopausal women and men; and human growth hormone deficiency and pediatric growth conditions.

See Also: The risks of owning bonds

Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly And Co (NYSE:LLY).

Institutional Ownership by Quarter for Eli Lilly And Co (NYSE:LLY)

Receive News & Ratings for Eli Lilly And Co Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly And Co and related companies with MarketBeat.com's FREE daily email newsletter.